Pharmacological Inhibitors of Glutamate Transport and Metabolism Suppress Oxidative Phosphorylation in Invasive Lobular Carcinoma (ENDO 2025) - Apr 27, 2025 - Abstract #OR30-08; Pres time: Jul 14, 2025; 03:00 PM - 03:15 PM; Location: Room 303; "Studies were conducted in four ILC cell lines (SUM44, LCCTam, MM134, MM134-LTED) treated with three pharmacological inhibitors: Riluzole (glutamate release inhibitor); R162 (inhibitor of glutamate dehydrogenase 1, GLUD1, which converts glutamate to aKG); and erastin (inhibitor of the glutamate:cystine antiporter xCT)...Treatment with erastin significantly increased free NADH levels in ETS cells (SUM44) and the two cell lines that are resistant to Tamoxifen (LCCTam, MM134), but not in MM134-LTED, a model of aromatase inhibitor resistance...These data suggest that GLUD1 inhibition in particular may be an effective therapeutic strategy in ILC cells, regardless of their response or resistance to ET. Future studies will determine whether combination therapies of GLUD1 inhibitors with ET will have superior anti-cancer efficacy compared to ET alone."
Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor
|
|
Dua Mobin 1; Ayodeji Olajuwon Olukoya 1; Shaymaa Bahnassy, PhD 2; Suman Ranjit, PhD 1; Todd Young, PhD 3; Rebecca Baab Riggins, PhD 1
|